Jung J, et al. - Via retrospectively reviewed records of 374 patients of type 2 diabetes with mild to moderate renal failure, the contributors intended to investigate whether the use of metformin during computed tomography (CT) with radiocontrast agents would increase the risk of contrast-induced nephropathy (CIN) and metabolic acidosis post-CT. During radiocontrast administration, 157 patients received metformin, and 217 patients were taking other oral hypoglycaemic agents (OHAs). Between the metformin use group and the other OHAs group, no significant difference in CIN incidence was observed. Furthermore, no relationship between metabolic acidosis after CT and the use of metformin was noted. However, metabolic acidosis post radiocontrast agent exposure was associated with malignant disease, low serum albumin level, and low serum total CO₂ level at baseline. Hence, other factors, but not metformin use, were associated with metabolic acidosis after radiocontrast agent exposure in patients with reduced renal function. No need for discontinuation of metformin before CT using radiocontrast agents in patients with mild to moderate renal failure was concluded by the authors.